Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Masked, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of RO7965032 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT07851259 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT07851259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07851259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Masked, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of RO7965032 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
August 21, 2030
Enrollment
321 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy secondary to age-related macular degeneration